Expression of nm23/nucleoside diphosphate kinase-a protein in endometrial carcinoma

Preeti J. Srivatsa, William A. Cliby, Gary L. Keeney, Vera J. Suman, William S. Harmsen, Steven C. Ziesmer, Patrick C. Roche, Karl C. Podratz

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

A metastatic tumor suppressor role for the nm23 gene product in breast carcinoma has been proposed. The biologic significance of nmg23/NDP kinase-A (NDPK-A) expression in endometrial carcinoma remains undetermined. We sought to (1) characterize the pattern and intensity of nm23 protein expression in endometrial carcinoma and (2) assess the relationship between intensity/pattern of nm23 protein immunostaining and treatment response assessed by progression-free survival and survival to death. Formalin-fixed paraffin-embedded sections from 234 patients with endometrial cancer were immunostained with a mouse monoclonal IgG to nm23/NDPK-A protein. In most specimens of endometrial carcinoma (67.5%), nm23 expression was strongly upregulated. No association was found between either intensity (0 vs 1, 2, 3) or pattern (nuclear membrane vs cytoplasmic) of immunostaining and FIGO stage, ploidy status, histologic subtype, myometrial invasion, progression- free survival, or survival to death. Absence of nm23 staining (0 vs 1, 2, 3) was significantly associated with lower tumor grades (P = 0.02). For stage I patients, moderate to strong nm23 immunostaining intensity (2, 3) was associated with a trend toward diminished progression-free survival (P = 0.08). Our data imply a heterogeneity of nm23 protein expression and possible distinct biologic roles for nm23 in endometrial compared with breast or ovarian carcinoma.

Original languageEnglish (US)
Pages (from-to)238-245
Number of pages8
JournalGynecologic oncology
Volume66
Issue number2
DOIs
StatePublished - Aug 1997

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this